Ubs Group Ag Ac Immune Sa Transaction History

Ubs Group Ag

$528 Billion
Q1 2025

A detailed history of Ubs Group Ag transactions in Ac Immune Sa stock. As of the latest transaction made, Ubs Group Ag holds 16,688 shares of ACIU stock, worth $28,369. This represents 0.0% of its overall portfolio holdings.

Number of Shares

16,688

Previous 49,678 66.41%

Holding current value

$28,369

Previous $134,000 76.87%

% of portfolio

0.0%

Previous 0.0%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 13, 2025	SELL	$1.87 - $2.98 $61,691 - $98,310	-32,990 Reduced 66.41%	16,688 $31,000
Q4 2024 Feb 14, 2025	BUY	$2.67 - $3.75 $93,583 - $131,437	35,050 Added 239.61%	49,678 $134,000
Q3 2024 Nov 14, 2024	SELL	$2.99 - $4.2 $4,520 - $6,350	-1,512 Reduced 9.37%	14,628 $55,000
Q2 2024 Aug 13, 2024	SELL	$2.29 - $4.87 $17,232 - $36,646	-7,525 Reduced 31.8%	16,140 $64,000
Q1 2024 May 13, 2024	SELL	$2.66 - $4.87 $56,751 - $103,901	-21,335 Reduced 47.41%	23,665 $70,000
Q4 2023 Feb 09, 2024	BUY	$2.46 - $5.0 $4,983 - $10,130	2,026 Added 4.71%	45,000 $225,000
Q3 2023 Nov 09, 2023	BUY	$2.77 - $3.38 $277 - $338	100 Added 0.23%	42,974 $122,000
Q4 2022 Feb 08, 2023	SELL	$1.72 - $3.12 $22,346 - $40,535	-12,992 Reduced 23.26%	42,874 $87,000
Q3 2022 Nov 10, 2022	BUY	$2.4 - $3.64 $2,498 - $3,789	1,041 Added 1.9%	55,866 $176,000
Q2 2022 Aug 10, 2022	BUY	$2.35 - $4.47 $84,600 - $160,920	36,000 Added 191.24%	54,825 $198,000
Q1 2022 May 16, 2022	SELL	$3.5 - $5.16 $257,841 - $380,132	-73,669 Reduced 79.65%	18,825 $75,000
Q4 2021 Feb 14, 2022	BUY	$4.83 - $7.56 $343,794 - $538,113	71,179 Added 333.94%	92,494 $457,000
Q3 2021 Nov 15, 2021	BUY	$6.2 - $8.34 $125,004 - $168,151	20,162 Added 1748.66%	21,315 $143,000
Q2 2021 Aug 13, 2021	BUY	$6.04 - $8.37 $1,981 - $2,745	328 Added 39.76%	1,153 $10,000
Q1 2021 May 12, 2021	SELL	$5.32 - $8.96 $17,008 - $28,645	-3,197 Reduced 79.49%	825 $6,000
Q4 2020 Feb 11, 2021	BUY	$4.47 - $5.58 $14,290 - $17,839	3,197 Added 387.52%	4,022 $21,000
Q3 2020 Nov 12, 2020	SELL	$4.78 - $9.06 $9,560 - $18,120	-2,000 Reduced 70.8%	825 $4,000
Q2 2020 Jul 31, 2020	BUY	$6.57 - $8.3 $13,140 - $16,600	2,000 Added 242.42%	2,825 $19,000
Q1 2020 May 01, 2020	SELL	$4.24 - $9.89 $4,579 - $10,681	-1,080 Reduced 56.69%	825 $6,000
Q4 2019 Feb 14, 2020	BUY	$4.56 - $8.78 $3,064 - $5,900	672 Added 54.5%	1,905 $16,000
Q3 2019 Nov 14, 2019	SELL	$4.8 - $5.89 $12,153 - $14,913	-2,532 Reduced 67.25%	1,233 $6,000
Q2 2019 Aug 14, 2019	SELL	$4.72 - $5.88 $1,618 - $2,016	-343 Reduced 8.35%	3,765 $21,000
Q1 2019 May 14, 2019	BUY	$3.65 - $11.68 $11,982 - $38,345	3,283 Added 397.94%	4,108 $21,000
Q4 2018 Feb 14, 2019	SELL	$7.35 - $11.7 $12,450 - $19,819	-1,694 Reduced 67.25%	825 $8,000
Q3 2018 Nov 14, 2018	BUY	$7.88 - $16.45 $19,849 - $41,437	2,519 New	2,519 $21,000
Q2 2018 Aug 14, 2018	SELL	$8.17 - $10.9 $17,312 - $23,097	-2,119 Closed	0 $0
Q1 2018 May 15, 2018	BUY	$10.34 - $13.78 $21,269 - $28,345	2,057 Added 3317.74%	2,119 $22,000
Q4 2017 Feb 14, 2018	BUY	$10.37 - $12.85 $642 - $796	62 New	62 $1,000
Q3 2017 Nov 14, 2017	SELL	$7.06 - $11.2 $8,168 - $12,958	-1,157 Closed	0 $0
Q2 2017 Aug 14, 2017	BUY	N/A	1,157	1,157 $10,000

Others Institutions Holding ACIU

# of Institutions

Shares Held

27.4M

Call Options Held

4.8K

Put Options Held

22.2K

View Full List

About AC Immune SA

Ticker ACIU
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,413,504
Market Cap $142M
Description
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectiv...

More about ACIU

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account